Novel Neoadjuvant Treatment Trial for Uveal Melanoma
Oral medication may have potential to preserve vision and shrink tumors prior to surgery or radiation
Related Articles
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Depression: A neuropsychoanalytic perspective
As a psychoanalyst, I believe that conscious mental phenomena (such as feelings) are not epiphenomenal to the workings of the brain. Feelings evolved for good…
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
PURPOSESWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly…
Mohamad Mohty: How to perform a high-quality peer review – OncoDaily
Mohamad Mohty: How to perform a high-quality peer review / cancer, Clin Hematol Int, Clinical Hematology International, fight against cancer, Global
The vast, sophisticated and fast-growing global enterprise that is Scam Inc
Online scamming leaves nobody safe
The Health Wrap: health and rights under siege, the local playbook, private sector disputes – and dogs on duty
Keeping up with the news exploding from the Trump Administration is “like drinking from a firehose”, Dr Lesley Russell writes
Want to keep schools safe? Hire more nurses
Arming every school with a school nurse would go a long way in casting a wider mental health safety net for students.
People love their salt, so make it healthier – Medical Republic
Potassium-enriched salt lowers blood pressure and is the new recommendation from the WHO.
Modeling study shows school closures’ varied impact on COVID-19 outcomes across 74 countries
School closures reduced the impact of COVID-19 in most countries but had negative effects in some, Monash University-led research encompassing 74 countries has found.
Long COVID: women at greater risk compared to men – could immune system differences be the cause?
A recent study has found women aged 40-54 had the greatest risk of developing long COVID.